MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Lexicon Pharmaceuticals Retained Earnings 2011-2026 | LXRX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Lexicon Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.97 B | -1.77 B | -1.59 B | -1.49 B | -1.4 B | -1.34 B | -1.47 B | -1.38 B | -1.25 B | -1.11 B | -1.1 B | -1 B | -900 M | -790 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -790 M | -1.97 B | -1.33 B |
Quarterly Retained Earnings Lexicon Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2 B | -1.99 B | -1.99 B | -1.97 B | -1.93 B | -1.87 B | -1.82 B | -1.72 B | -1.67 B | -1.62 B | -1.59 B | -1.56 B | - | -1.51 B | -1.49 B | -1.46 B | -1.44 B | -1.42 B | -1.4 B | -1.4 B | -1.4 B | -1.4 B | -1.34 B | -1.34 B | -1.52 B | -1.34 B | -1.47 B | -1.47 B | -1.47 B | -1.47 B | -1.37 B | -1.38 B | -1.38 B | -1.38 B | -1.25 B | -1.25 B | -1.25 B | -1.25 B | -1.11 B | -1.11 B | -1.11 B | -1.11 B | -1.1 B | -1.1 B | -1.1 B | -1.1 B | -1 B | -1 B | -1 B | -1 B | -900 M | -900 M | -900 M | -900 M | -790 M | -790 M | -790 M | -790 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -790 M | -2 B | -1.34 B |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
-3.01 B | $ 20.29 | -1.98 % | $ 2.56 B | USA |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 0.8 | -5.3 % | $ 4.36 M | China |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
-1.31 B | $ 166.0 | -0.23 % | $ 8.26 B | USA |
 |
AbCellera Biologics
ABCL
|
-29.5 M | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Certara
CERT
|
-130 M | $ 7.22 | 2.34 % | $ 1.16 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
474 M | $ 23.78 | -0.42 % | $ 2.91 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-335 M | $ 18.17 | 1.57 % | $ 873 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-104 M | $ 17.9 | -1.38 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
-76.8 M | $ 40.5 | -1.29 % | $ 11 B | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Galectin Therapeutics
GALT
|
-402 M | $ 2.89 | -5.56 % | $ 180 M | USA |
 |
Capricor Therapeutics
CAPR
|
-159 M | $ 26.3 | -2.08 % | $ 704 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-563 M | $ 1.02 | -0.33 % | $ 74.9 M | USA |
 |
Galapagos NV
GLPG
|
-335 M | $ 33.13 | -2.82 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
-66.2 M | $ 27.88 | 1.79 % | $ 363 M | USA |
 |
Galecto
GLTO
|
-256 M | $ 29.63 | -1.41 % | $ 787 M |  Danmark |
 |
Genmab A/S
GMAB
|
7.11 B | $ 27.66 | -6.71 % | $ 17.7 B | Danmark |
 |
Halozyme Therapeutics
HALO
|
54.8 M | $ 68.58 | -1.82 % | $ 8.22 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | Canada |
 |
Hoth Therapeutics
HOTH
|
-60.4 M | $ 1.0 | -1.47 % | $ 6.38 M | USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Harmony Biosciences Holdings
HRMY
|
161 M | $ 28.32 | -2.01 % | $ 1.63 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
ImmuCell Corporation
ICCC
|
-14.2 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
-1.96 B | $ 3.27 | -2.1 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-562 M | $ 28.57 | -2.16 % | $ 1.66 B | USA |
 |
Immuron Limited
IMRN
|
-68.4 M | $ 0.75 | -0.69 % | $ 6.46 M |  Australia |
 |
Immunic
IMUX
|
-609 M | $ 1.13 | 6.61 % | $ 176 M | USA |
 |
Immunovant
IMVT
|
-1.24 B | $ 27.09 | -2.38 % | $ 4.11 B | USA |
 |
Inhibrx
INBX
|
-614 M | $ 76.39 | -1.42 % | $ 3.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
-101 M | $ 0.8 | -2.44 % | $ 1.96 M | Canada |